U.S. patent application number 10/059635 was filed with the patent office on 2002-08-01 for polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals.
Invention is credited to Uang, Herling, Wei, Shifeng Bill.
Application Number | 20020102308 10/059635 |
Document ID | / |
Family ID | 22792792 |
Filed Date | 2002-08-01 |
United States Patent
Application |
20020102308 |
Kind Code |
A1 |
Wei, Shifeng Bill ; et
al. |
August 1, 2002 |
Polyethylene glycol coating for electrostatic dry deposition of
pharmaceuticals
Abstract
The invention relates to a substrate coating for the
electrostatic deposition of dry powder medicaments for use in the
manufacture of pharmaceutical dosage forms comprising micronized
polyethylene glycol (PEG), with A molecular weight in the range of
1,000 to 20,000, and having a particle size of 1-100 .mu.m. The
invention also relates to pharmaceutical compositions having such a
substrate coating, and processes for manufacturing such
pharmaceutical compositions. The invention also relates to the
technology of reversing negative charge of medicaments so that they
can be electrostatically deposited on a negatively charged
substrate.
Inventors: |
Wei, Shifeng Bill; (Belle
Mead, NJ) ; Uang, Herling; (Somerset, NJ) |
Correspondence
Address: |
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
22792792 |
Appl. No.: |
10/059635 |
Filed: |
January 29, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10059635 |
Jan 29, 2002 |
|
|
|
09212886 |
Dec 16, 1998 |
|
|
|
6372246 |
|
|
|
|
Current U.S.
Class: |
424/486 ;
427/2.19 |
Current CPC
Class: |
A61K 9/2086 20130101;
A61K 9/2095 20130101 |
Class at
Publication: |
424/486 ;
427/2.19 |
International
Class: |
A61K 009/14; B01J
013/00 |
Claims
What is claimed is:
1. A substrate coating for the electrostatic deposition of dry
powder medicaments for use in the manufacture of pharmaceutical
dosage forms comprising micronized polyethylene glycol (PEG), with
molecular weight in the range of 1,000 to 20,000, and having a
particle size of 1-100 .mu.m.
2. The substrate coating of claim 1 having a melting point in the
range of 50-63.degree. C.
3. The substrate coating of claim 1 wherein the PEG has a molecular
weight in the range of 6,000-8,000.
4. The substrate coating of claim 1 also containing a
plasticizer.
5. The substrate coating of claim 4 wherein the plasticizer is
selected from castor oil, polyethylene glycol, propylene glycol or
glycerine.
6. The substrate coating of claim 1 also containing one or more
coloring, pacifying, flavoring and/or sweetening agents.
7. A pharmaceutical composition comprising an edible substrate
having micronized drug substance with a particle size of 1-100
.mu.m deposited on the surface of the substrate by electrostatic
dry powder deposition, and a film coating on the substrate and drug
substance consisting essentially of micronized polyethylene glycol
(PEG), with molecular weight in the range of 1,000 to 20,000, and
having a particle size of 1-100 .mu.m.
8. The pharmaceutical composition of claim 7 wherein the film
coating has a melting point in the range of 50-63.degree. C.
9. The pharmaceutical composition of claim 7 wherein the PEG has a
molecular weight in the range of 6,000-8,000.
10. The pharmaceutical composition of claim 7 wherein the PEG film
coating (dried) constitutes from about 1 to about 10, percent by
weight of the total weight of the solid dosage form.
11. The pharmaceutical composition of claim 7 wherein the edible
substrate is comprised of a tablet core.
12. The pharmaceutical composition of claim 8 wherein the tablet
core is prepared by compressing a mixture of microcrystalline
cellulose (99-99.5%) and magnesium stearate (0.5-1%).
13. The pharmaceutical composition of claim 7 wherein the drug
substance is selected from one or more estrogens and/or
progestins.
14. The pharmaceutical composition of claim 13 wherein the drug
substance is a combination of norgestimate and ethinyl
estradiol.
15. In a process for manufacturing pharmaceutical unit dosage forms
by the electrostatic deposition of dry powder medicament to a
substrate, the improvement comprising coating the substrate in
place with dry micronized polyethylene glycol (PEG), melting the
dry polyethylene glycol coating and allowing it to cool whereupon a
protective coating is formed.
16. A method of depositing negatively charged dry powder medicament
on a negatively charged substrate by an electrostatic dry powder
deposition process, the method comprising reversing the charge of
the medicament to a positive charge by mixing the negatively
charged medicament with micronized polyethylene glycol (PEG), at
the ratio of medicament to PEG of 1:1 to 1:60, and then depositing
the mixture onto the negatively charged substrate.
17. The method according to claim 16 wherein the PEG has a
molecular weight in the range of 1,000 to 20,000 and a particle
size of 1-100 .mu.m.
18. The method according to claim 16 wherein the PEG has a melting
point in the range of 50-63.degree. C.
19. The method according to claim 16 wherein the PEG has a
molecular weight in the range of 6,000 to 8,000.
Description
FIELD OF THE INVENTION
[0001] The invention relates to substrate coatings for the
electrostatic deposition of dry powder medicaments for use in the
manufacture of pharmaceutical dosage forms. The invention also
relates to the technology of reversing negative charge of
medicaments so that they can be deposited on a negatively charged
substrate. More particularly, the invention relates to polyethylene
glycol substrate coatings for the dry powder electrostatic
deposition of medicinal substances. The invention also provides the
means of employing polyethylene glycol to reverse the negative
charge of medicaments so that they can be deposited on a negatively
charged substrate.
BACKGROUND OF THE INVENTION
[0002] It has been proposed for sometime that dry powdered
medicaments be delivered orally by electrostatically depositing the
dry medicament onto an edible substrate which could be administered
to the patient. The substrate with the medicament deposited thereon
is administered to the patient directly or is applied to a placebo
tablet which can be administered to the patient. The technology has
potential advantages in enhanced safety, enhanced stability, and
efficient product development and manufacturing.
[0003] One example of this technique is disclosed in U.S. Pat. No.
4,197,289 (the '289 patent). This patent discloses solid unit
dosage forms for oral administration comprising an edible "web"
having the medicament deposited thereon where the web is fabricated
into a dosage form in which the deposited medicament is sealed. The
dosage forms are manufactured by using an electrostatic charging
technique. In this technique, the edible web is passed through an
electrostatic field in a suitable chamber. Finely particulate
active ingredient is introduced into the chamber and is deposited
onto the web as it passes over an oppositely charged roller.
Dosages are regulated by measuring spectroscopically the amount of
medicament that has been deposited on the web and fabricating an
appropriate dosage form with the required amount of medicament. In
this technique, the edible web used for depositing the medicament
is an edible material with a resistivity capable of enabling the
deposition thereon of dielectric particles. Paper and polymeric web
formulations are disclosed. The polymeric webs are prepared from an
organic film forming polymer such as cellulose derivatives in
combination with plasticizers, modifiers and fugitive solvents.
[0004] Another technique is disclosed in U.S. Pat. No. 5,714,007
(the '007 patent). In this patent there is disclosed an apparatus
and method for electrostatically depositing select doses of
medicament powder at select locations on a substrate. The '007
patent technique involves charging a predefined region of a
substrate with a controlled amount of charge. Oppositely charged
medicament powder is then exposed to the charged substrate so that
the powder medicament adheres to the charged substrate. The
quantity and position of charge accumulated on the substrate and
the charge-to-mass ratio of the medicament powder can be used to
accurately control the dosage of medicament applied to the
substrate and the position of the medicament on the substrate. The
substrate is then encapsulated in an inert material to form a
capsule, tablet, or suppository. It is suggested that the
substrates can vary widely depending upon the ultimate application
of the medication. For oral medications, polymeric substances such
as cellulose are disclosed.
[0005] In each of these techniques it is suggested that the dry
powder can be applied directly to the surface of the edible
substrate and the substrate can either be divided into unit dosage
forms or encapsulated in an inert material to form a capsule,
tablet or suppository. In either case, when the dry medicament
powder is deposited directly onto a dosage form substrate, a
coating is required. The deposited drug powder is as loose as dust
on the surface of a furniture. To prevent drug powder from being
wiped off or from losing potency during subsequent processing and
packaging, the product needs a protective coating.
[0006] Various materials are used as film coatings in tablet
manufacture but in practice conventional polymeric coatings are not
all suitable. Polymeric films typically used in such film coating
include (1) vinyl polymers such as polyvinylpyrrolidone, polyvinyl
alcohol and acetate, (2) cellulosics such as methyl and ethyl
cellulose, hydroxyethyl cellulose and hydroxypropyl
methylcellulose, (3) acrylates and methacrylates, (4) copolymers
such as the vinyl-maleic acid and styrene-maleic acid types, and
(4) natural gums and resins such as zein, gelatin, shellac and
acacia. See Remington's Pharmaceutical Sciences, 15th Ed. Mack
Publishers (1975) p. 1613.
[0007] For the present purposes, the coating needs to be applied to
the individual dosage forms precisely and in place. The
conventional coating of tablets is random coating. The process
includes spraying the coating solution onto a tablet bed while the
tablet bed is tumbling in a coating pan. A coating film is formed
on the tablets when water or solvent is dried at elevated
temperature during coating. The conventional coating is suitable
for conventional pharmaceutical dosage forms, tablets or capsules,
since the drug substance is embedded or encapsulated in the tablet
matrix or capsules. But the conventional coating is not suitable
for deposited tablets produced by Electrostatic Dry Deposition
technology due to the tumbling of the tablet bed. The coating
should be in-place: the deposited tablet or product needs to be
coated before it comes in contact with other tablets. In the mean
time, the coating should be precise: all coating solution should be
on the tablet. Any spill may cause insulation of or interference
with the electronic equipment. Accordingly, there is a need for a
protective substrate coating which is suitable for the
electrostatic deposition of dry powder medicaments which can be
applied in place and precisely.
[0008] Another problem that is encountered in the above described
electrostatic deposition method is that the triboelectric charging
process generally produces positively charged drug substances and
negatively charged substrate. However, some drug substances can
only be negatively charged and would not be suitable for use with a
negatively charged substrate. Accordingly, a need exists for a
method of depositing negatively charged drug substance on a
negatively charged substrate.
SUMMARY OF THE INVENTION
[0009] The invention relates to a substrate coating for the
electrostatic deposition of dry powder medicaments for use in the
manufacture of pharmaceutical dosage forms comprising micronized
polyethylene glycol (PEG), with molecular weight in the range of
1,000 to 20,000, and having a particle size of 1-100 .mu.m.
[0010] The invention also relates to an improvement in the process
for manufacturing pharmaceutical unit dosage forms by triboelectric
charging and the electrostatic deposition of dry powder medicament
to a substrate, the improvement comprising coating the substrate in
place with dry micronized polyethylene glycol (PEG), melting the
dry polyethylene glycol coating and allowing it to cool whereupon a
protective coating is formed.
[0011] In a further aspect of the invention, a method of depositing
negatively charged dry powder medicament on a negatively charged
substrate by an electrostatic dry powder deposition process is
provided, the method comprising reversing the charge of the
medicament to a positive charge by mixing the negatively charged
medicament with micronized polyethylene glycol (PEG), at the ratio
of medicament to PEG of 1:1 to 1:40, and then depositing the
mixture onto the negatively charged substrate. Once the charged
mixture is deposited on the substrate surface, it is melted and
cooled whereupon a protective film is formed while cooling.
[0012] In a further aspect of the invention, a pharmaceutical
composition is provided comprising an edible substrate having
micronized drug substance with a particle size of 1-100 .mu.m
preferably 5-20 .mu.m, deposited on the surface of the substrate by
electrostatic dry powder deposition, and a film coating on the
substrate and drug substance consisting essentially of micronized
polyethylene glycol (PEG), with molecular weight in the range of
1,000 to 20,000, and having a particle size of 1-100 .mu.m. In a
preferred embodiment, the edible substrate is comprised of a tablet
core. Preferably, the drug substance is selected from one or more
estrogen and/or progestins, preferably norgestimate and ethinyl
estradiol.
DETAILED DESCRIPTION
[0013] The use of micronized PEG as a protective coating in
accordance with the present invention provides several unique
advantages. PEG has a low contact angle. Therefore, it can
penetrate through the deposited powder and make contact with the
substrate surface. As a result, PEG can form a strong coating even
in the presence of loose powder between coating film and substrate.
Further, PEG has a desirable melting range: 50-63.degree. C.,
depending on the molecular weight. This melting point is
prodigiously suited for the present purposes since melting points
lower than 40-50.degree. C. may cause sticking and flow problems
during processing and packaging, while melting points higher than
65-70.degree. C. may cause slow dissolution, and low
bioavailability of drug products. Moreover, PEG is water soluble.
Its coating will not delay the dissolution of drug products.
Therefore, PEG will not affect bioavailability of drug
products.
[0014] Furthermore, the PEG coating of the present invention can be
applied to the substrate precisely and in-place to avoid spillage
and interference with the electronic deposition equipment. PEG is
deposited in place by completion of the deposition process while
substrates are still on the tray, platform, or conveyer belt. The
in-place coating can avoid detachment of the medicaments in a
tablet bed as encountered in the conventional tumbling-dry coating
process. Moreover, the protective coating formed by the micronized
PEG of the present invention provides a pharmaceutically elegant
cosmetic coating into which colorants and other additives can be
incorporated to improve the appearance, feel and dissolution
characteristics.
[0015] In another aspect of the invention, as stated above, the
coating process of the present invention can be employed to reverse
the charge of negatively charged drug substance for deposition on a
negatively charged substrate. Triboelectric charging can only
produce one particular charge, positive or negative charge, for a
particular substance or medicament. By employing the micronized PEG
at the described mixing ratio, the negatively charged drug
substance can be converted to a positively charged powder for
deposition. The uniqueness of the process lies in the PEG molecule
which contains abundant oxygen atoms. The oxygen atoms are
electronegative, i.e., they pull electrons to them. The surplus
electrons demonstrate as a negative charge of drug substance. Once
PEG mixes with drug substance, the oxygen atoms in PEG molecule
will "neutralize" the surplus electrons of drug substance. As a
result, the mixture of PEG and drug substance demonstrate a net
positive charge. Therefore, the mixture can be deposited to the
negatively charged substrate.
[0016] In accordance with the present invention, the PEG coating is
formed on at least a portion, preferably on all, of the exposed
surface of the substrate containing the pharmaceutical actives. The
substrate may be an edible polymer film or may be a pharmaceutical
tablet core or placebo tablet. Suitable polymer films which may be
used as edible substrates are selected from art recognized nontoxic
organic film formers such as natural and chemically modified
starches and dextrins, proteins such as gelatins; cellulose
derivatives such as sodium carboxymethylcellulose,
hydroxypropylmethylcellulose and the like; other polysaccharides
such as pectin, xanthan gum, guar gum, algin and the like; and
synthetic film forming polymers such as polyvinylpyrrolidone.
Suitable polymer substrates are disclosed in U.S. Pat. No.
4,029,758, hereby incorporated by reference. Suitable tablet cores
or placebo tablets which may be used as substrates are selected
from art recognized tableting ingredients. The cores are prepared
in accordance with standard pharmaceutical tableting techniques,
including wet-granulation, dry-granulation, direct compression,
spheronization and the like. Preferably the tablet cores are
prepared by compressing a mixture of microcrystalline cellulose
(99-99.5%) and magnesium stearate (0.5-1%).
[0017] The PEG film coating may optionally contain a plasticizer,
such as castor oil, polyethylene glycol, propylene glycol or
glycerine, but in most cases a plasticizer will not be required.
The coating may also contain a coloring or pacifying agent. The
film coating may also contain a flavoring and/or sweetening agent
to improve palatability.
[0018] The preferred PEG coating material will generally be
composed of micronized PEG having a molecular weight in the range
of 1,000 to 20,000 and a particle size of 1-100 .mu.m, with a
melting point in the range of 50-63.degree. C. Preferably PEG
6000-8000, is employed. The PEG material is micronized by way of
air attrition, e.g., by use of a Jetmill, to a particle size of
1-100 .mu.m, preferably 5-10 .mu.m. Obviously equivalents for these
compounds as are well known in the tablet coating art, may be used
in approximately the same proportions.
[0019] The protective coating is applied to the substrate as a dry
powder by electrostatic dry deposition using the techniques known
in the art such as those disclosed in U.S. Pat. Nos. 4,029,758,
5,714,007, 5,788,814 and 5,470,603, hereby incorporated by
reference. Once the dry coating powder is deposited on the surface
of the substrate, it is melted and cooled to form a thin film
coating.
[0020] The PEG film coating (dried) generally constitutes from
about 1 to about 10, preferably about 2 to about 6, percent by
weight of the total weight of the solid dosage form.
[0021] The PEG film coatings of the present invention may be
employed for the coating of a variety of medicaments where
electrostatic deposition manufacturing techniques are desirable.
Typically, the active ingredient will be a dry powder medicament in
which small (i.e. microgram) dosages are needed and where exposure
to the active ingredient during manufacture must be kept to a
minimum, for example hormones or cytotoxic medicaments. These
medicaments are most suited for electrostatic dry deposition
processes. The preferred pharmaceutical tablets with which the PEG
protective coatings of the present invention is used contains an
estrogen optionally in combination with a progestin for use as oral
contraceptives. Preferably, the estrogen component is employed in a
daily dosage equivalent to about 0.020-0.050 mg of ethinyl
estradiol, preferably about 0.030 mg ethinyl estradiol equivalent.
The progestin component is preferably administered in a daily
dosage corresponding in progestational activity to 0.065-2.0 mg
norethindrone per day. Norgestimate in an amount of about 30-250
.mu.g with or without 35 .mu.g of ethinyl estradiol is preferred.
Other active ingredients which may be employed include cytotoxic
agents, estradiol, estradiol cypionate, estradiol valerate,
esterified estrogens, estrone, estropipate, quinestrol, mestranol,
levonorgestrel, norethindrone, norgestrel and progesterone
[0022] Specific embodiments of the present invention are
illustrated by way of the following examples. This invention is not
confined to the specific limitations set forth in these examples,
but rather to the scope of the appended claims. Unless otherwise
stated, the percentages and ratios given below are by weight.
EXAMPLE 1
Norgestimate Tablet
[0023] PEG with molecular weight in the range of 1,000 to 20,000,
preferably PEG 6000-8000, is micronized by way of air attrition,
e.g., Jetmill, to a particle size of 1-100 .mu.m, preferably 5-10
.mu.m. Norgestimate is micronized separately to particle size of
1-100 .mu.m, preferably 5-20 .mu.m. A placebo tablet is made by
compressing the mixture of microcrystalline cellulose (99-99.5%)
and magnesium stearate (0.5-1%). Placebo tablets are arranged in a
tray of 9 tablets by 9 tablets array for deposit. Micronized
norgestimate powder is triboelectrically charged. The amount of
norgestimate to be deposited is based on the norgestimate
charge/mass ratio. Adjust the charge of the substrate so that 250
.mu.g of norgestimate is deposited on the substrate (placebo
tablet) surface. Micronized PEG 8000 is triboelectrically charged,
and deposited on top of norgestimate. Adjust the charge to deposit
PEG in the range of 0.1-1.5 mg. Surface deposited PEG is placed
under Infrared lamp until melted. PEG will form a coating film
while cooling. In the similar manner, deposit PEG and coat bottom
side and rest of the tablet surface.
EXAMPLE 2
Norgestimate Tablet with Marketing Image
[0024] In most cases, substrate needs to incorporate colorant to
give the dosage form a traditional appearance. PEG with molecular
weight in the range of 1,000 to 20,000, preferably PEG 6000-8000,
is micronized by Jetmill together with a colorant, e.g., iron
oxide, to particle size of 5-10 .mu.m. Micronized norgestimate
powder is triboelectrically charged, and deposited on the substrate
surface. Micronized PEG 6000/iron oxide mixture is
triboelectrically charged, and deposited on top of norgestimate.
Surface deposited PEG is placed under Infrared lamp until melt. PEG
will form a coating film while cooling. In the similar manner,
deposit PEG/iron oxide mixture and coat bottom side and rest of the
tablet surface.
[0025] Tablet with marketing image can also be produced by coating
micronized PEG on colored placebo tablets. Colored placebo tablet
can be made by compressing the microcrystalline cellulose (99%),
magnesium stearate (0.5%), iron oxide (0.05%).
EXAMPLE 3
Norgestimate/Ethinyl Estradiol Tablet
[0026] PEG with molecular weight in the range of 1,000 to 20,000,
preferably PEG 6000-8000, is micronized by Jet mill together with
ethinyl estradiol at the ratio of ethinyl estradiol to PEG 1:1 to
1:60, preferably 1:30 to 1:42. Adjust Jet mill to produce particle
size of 1-100 .mu.m, preferably 5-10 .mu.m. Micronized norgestimate
powder is electrically charged, and deposited on the substrate
surface. Micronized PEG 6000/ethinyl estradiol mixture is
electrically charged, and deposited on top of norgestimate. Surface
deposited PEG is place under Infrared lamp until melt. PEG will
form a coating film while cooling. In the similar manner, deposit
PEG ethinyl estradiol mixture and coat bottom side and rest of the
tablet surface. Adjust the charge of the substrate so that total of
250 .mu.g of norgestimate and 35 .mu.g of ethinyl estradiol are
deposited on the substrate (placebo tablet) surface.
EXAMPLE 4
Norgestimate Tablet with Marketing Image
[0027] Placebo tablets are arranged in a tray of 9 tablets by 9
tablets array for deposit. PEG 6000, is micronized by Jetmill
together with iron oxide to particle size of 5-10 .mu.m.
Norgestimate is micronized separately to particle size of 5-15
.mu.m. Micronized norgestimate powder is triboelectrically charged,
and deposited on the substrate surface. Micronized PEG 6000/iron
oxide mixture is triboelectrically charged, and deposited on top of
norgestimate. Surface deposited PEG is place under infrared lamp
until melt. Turn off the infrared lamp. PEG will form a coating
film while cooling. In the similar mannet, deposit PEG/iron oxide
mixture and coat bottom side and rest of the tablet surface.
EXAMPLE 5
Norgestimate/Ethinyl Estradiol Tablet
[0028] PEG 8000 is micronized by Jet mill together with ethinyl
estradiol at the ratio of ethinyl estradiol to PEG from 1:1 to
1:60. Adjust Jet mill to produce particle size of 5-10 .mu.m.
Norgestimate is micronized separately to particle size of 5-15
.mu.m. Micronized norgestimate powder is electrically charged, and
deposited on the substrate surface. Micronized PEG 8000/ethinyl
estradiol mixture is triboelectrically charged, and deposited on
top of norgestimate.
[0029] Surface coating is accomplished by melting deposited PEG and
cooling to form the coating. In the similar manner, deposit PEG
only or PEG ethinyl estradiol mixture and coat bottom side and rest
of the tablet surface. Adjust the charge of the substrate so that
total of 250 .mu.g of norgestimate and 35 .mu.g of ethinyl
estradiol are deposited on the substrate (placebo tablet)
surface.
* * * * *